Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obatoclax with Carboplatin and Etoposide in ES-SCLC
NCT00682981Phase 2Completed
- Sponsor
- Gemin X Pharmaceuticals
- Start
- May 2008
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of obatoclax in small cell lung cancer (SCLC) (4 arms), sponsored by Gemin X Pharmaceuticals. Primary endpoints: Recommended Phase II Dose at 6 months and Objective Response Rate at 6 months. Started May 2008; status: completed.
02
Drugs
obatoclax
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00682981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00682981.